Media

April 12, 2018

Terumo and Quirem Medical welcome the positive reimbursement decision for QuiremSpheres® in the Netherlands

Terumo and Quirem Medical welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver metastases in the salvage setting[1]. The National Healthcare Institute (‘Zorginstituut’) concludes that radioembolization treatment with holmium-166 microspheres, which has been developed in the Netherlands, meets “established medical science and medical practice”[2] for this indication.

QuiremSpheres®, the next generation of SIRT microspheres, are the only commercially available microspheres that contain the radioactive isotope holmium-166. Recent trials have shown the safety and efficacy of holmium microspheres for the treatment of advanced liver cancer.[3]  QuiremSpheres® can be visualized by means of both SPECT and MRI. This allows clinicians to assess quantitatively the distribution of microspheres in the liver enabling the dose to tumor and dose to normal tissue to be calculated accurately. This Dutch innovation fits within a trend in the field of radiotherapy to verify the absorbed radiation dose after the treatment.[4]

To read the full press release, click here.

[1] Zorginstituut, ‘Standpunt holmium-166 radioembolisatie (QuiremSpheresâ) bij inoperabele levertumoren’, 2018, p.5, p.43

[2] Ibidem

[3] Smits et al, Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study, Lancet Oncology 2012, oct;13(10):1025-34 ; Prince et al, ‘Efficay of radioembolization with holmium-166 microspheres in salvage patients with liver metastases’, Journal of Nuclear Medicine, sept.2017

[4] Council Directive 2013/59/Euratom, effective Feb 6th 2018